Francesco De Prospero

Francesco De Prospero advises public and private companies, investors, private equity firms, institutions and nonprofits on transactions involving corporate and intellectual property matters, including mergers and acquisitions, technology transfers, collaborations, joint ventures, and the licensing, development and commercialization of new products and technologies.

In his pro bono practice, Mr. De Prospero has handled matters ranging from asylum cases to the representation of numerous nonprofit organizations supporting the arts, social services and environment protection efforts.

While in law school, Mr. De Prospero served on the editorial board of the University of Pennsylvania Journal of International Law as articles editor and was a judicial intern to Judge Michael Baylson of the Eastern District of Pennsylvania and Justice Jack Jacobs of the Delaware Supreme Court.

Before receiving his first law degree in Europe, Mr. De Prospero was an infantry lieutenant in the Italian Army and received his basic training in the Alpini, the Italian mountain troops.

Experience

Broadcom in its sale of certain assets and manufacturing rights associated with its wireless IoT business to Synaptics.
GlaxoSmithKline in a $300 million equity investment in data company 23andMe.
Bain Capital in the sale of The Weather Company’s B2B, mobile and cloud-based web properties to IBM to be used as the foundation for the Watson IoT Platform for approximately $3 billion.
Luminous Computing, a supercomputer manufacturer, in its commercial operations and intellectual property transactions.

Several biotech public companies in the negotiation of master development and service agreements with respect to clinical and real-world evidence studies of their leading products.
Merck in its investment in, and option and collaboration agreement with, biotech KalVista Pharmaceuticals for an upfront option fee of $37 million and potential milestone payments up to $715 million.
Allergan in a license and option agreement with Whitecap Biosciences for certain products for the treatment of glaucoma for a one-time payment of $175 million and up to $300 million in royalties and milestones.
Eisai in a marketing, supply and distribution agreement for the exclusive right to commercialize a branded product in Central and South America.
Gilead in the negotiation with Japan Tobacco of the transfer back to Gilead of all rights to its HIV products in exchange for total payments up to $560 million.

Amgen in its $13.4 billion acquisition of worldwide rights to Otezla from Celgene Corporation in connection with Celgene’s previously announced merger with Bristol-Myers Squibb.
Biohaven in the co-promotion arrangement with a global pharmaceutical company for the development and marketing of an innovative migraine drug (Nurtec) in ex-US territories.
The Leukemia & Lymphoma Society in a partnership and co-funding agreement with a European biotech company to further preclinical and clinical development of a targeted therapy for acute myeloid leukemia.
Sanofi in the definitive agreement to acquire a therapy for a form of thyroid carcinoma (Caprelsa) for approximately $300 million in upfront and milestone payments.
Pfizer in its buy-back of the rights to a collaboration with biotech Protalix in exchange of $46 million in cash and stocks.

Samsung in its $2.5 billion initial investment in a joint venture, and related commercial agreements, with Stellantis to build a EV battery plant in Indiana with an initial annual production capacity of 23 gigawatt that will create 1,400 new jobs.
Fiat Chrysler Automobiles in its $60 billion 50/50 merger with Peugeot creating the fourth-largest automaker and in various related spin-out transactions.
Stellantis in its sale of its global cast iron automotive components to Tupy SA.
Philip Morris International in a transfer of assets, license/option and distribution agreement with respect to its branded IQOS line of products in the United States.
Amazon in its bid to acquire rights to broadcast first division soccer games in Europe.

Dunkin’ Brands in connection with various intellectual property matters related to a $2.6 billion securitization financing.

ConsenSys AG (industry-leading blockchain software company) in its reorganization and contribution agreement with J.P. Morgan.
Capital One in its acquisition of TripleTree, an investment banking advisory platform serving healthcare companies.
Colony Capital in its sale of a minority stake in its Digital Colony investment management platform to Wafra Inc.
The Carlyle Group, Bain Capital, TPG Growth, Silver Lake Partners, Welsh, Carson, Kohlberg & Co., KKR on strategic IP and technology investments and financings in software and data companies.

The World Wildlife Fund (WWF) and the Institute of Food Technologists (IFT) in the launch of the first-ever global industry standards for seafood traceability (Global Dialogue on Seafood Traceability or GDST) involving more than 60 companies and associations.
A 138-year-old nonprofit health care organization in a merger agreement creating a 2,000-person agency with more than $115 million in annual revenues and committed to serving children and families in need throughout the New England region.

Experience

Perspectives

Credentials

Francesco De Prospero

Experience

Perspectives

Credentials

Email Disclaimer